Citations

Mayo Clinic

Showing 10 of 108551 citations.

Molecular classification of cancer with the 92-gene assay in cytology and limited tissue samples
Brachtel, Elena F. , Operaña, Theresa N., Sullivan, Peggy , Kerr, Sarah E. , Cherkis, Karen, Schroeder, Brock E. , Schnabel, Catherine A. , Dry, Sarah

Oncotarget | March 29, 2016 | Volume: 7 | Issue: 19 | Pages: 27220-27231

10.18632/oncotarget.8449 | PMID 27034010 Get It

Implementation of Clinical Decision Support Rules to Reduce Repeat Measurement of Serum Ionized Calcium, Serum Magnesium, and N-Terminal Pro-B-Type Natriuretic Peptide in Intensive Care Unit Inpatients
Moyer, Ann M. , Saenger, Amy K., Baumann, N, Block, Darci R , Botz, Chad M. , Jaffe, Allan S. , Hanson, Curtis A. , Karon, Brad S. , Willrich, Maria, Donato, Leslie J. , Baumann, Nikola A, Khan, Munawwar A., Willrich, Maria Alice V. , Khan, Munawwar Ali , Jaffe, Allan S.

Clinical Chemistry | March 28, 2016 | Volume: 62 | Issue: 6 | Pages: 824-830

10.1373/clinchem.2015.250514 | PMID 27022069 Get It

Abstract BACKGROUND We assessed the impact of clinical decision support (CDS) rules within the electronic health record for ionized calcium (iCa), serum magnesium (Mg), and N-terminal pro-B-type natriuretic peptide (NT-proBNP) in intensive care unit (ICU) inpatients at a large academic center. METHODS A repeat order for measurement of iCa or Mg placed within 24 (iCa) or 48 (Mg) h of a previously nonactionable result, or additional orders for NT-proBNP beyond 1 within a single hospitalization, triggered a CDS pop-up alert showing the prior result and offering the opportunity to cancel the order or to place the order after entering an indication for repeat testing. The number of tests performed for each of these analytes and incidence of adverse clinical outcomes potentially associated with hypocalcemia or hypomagnesemia were compared between the 90-day period before CDS implementation and two 90-day periods immediately following. RESULTS iCa test volumes decreased by 48%, Mg by 39%, and NT-proBNP by 28% in the 90-day period immediately following implementation and remained decreased by 54%, 49%, and 22%, respectively, during the following 90-day period (all P values <0.0002). Adverse clinical outcomes potentially associated with hypocalcemia or hypomagnesemia did not increase (all P-values >0.17). CONCLUSIONS Implementation of CDS dramatically decreased repeat testing of iCa, Mg, and NT-proBNP without adversely impacting clinical outcomes in the ICU. Expansion of the rules from the ICU units to include the entire hospitalized patient population and expansion to additional analytes is expected to lead to further reductions in testing.
Evolving Techniques in Pancreatic Surgery
Radenković, Dejan , Farnell, Michael B., Bassi, Claudio, Besselink, Marc G. , Salvia, Roberto , Besselink, Marc G

Gastroenterology Research and Practice | March 28, 2016 | Volume: 2016 | Issue: No issue available | Pages: 1-2

10.1155/2016/4289724 | PMID 27118968 Get It

Vascular Toxicities of Cancer Therapies
Herrmann, Joerg , Yang, Eric H. , Iliescu, Cezar , Charitakis, Konstantinos, Hakeem, Abdul , Toutouzas, Konstantinos , Leesar, Massoud A. , Marmagkiolis, Konstantinos , Iliescu, Cezar A, Cilingiroglu, Mehmet , Grines, Cindy L. , Çilingiroğlu, Mehmet , Yang, Eric

Circulation | March 28, 2016 | Volume: 133 | Issue: 13 | Pages: 1272-1289

10.1161/circulationaha.115.018347 | PMID 27022039 Get It

Since the late 1990s, there has been a steady decline in cancer-related mortality, in part related to the introduction of so-called targeted therapies. Intended to interfere with a specific molecular pathway, these therapies have, paradoxically, led to a number of effects off their intended cancer tissue or molecular targets. The latest examples are tyrosine kinase inhibitors targeting the Philadelphia Chromosome mutation product, which have been associated with progressive atherosclerosis and acute vascular events. In addition, agents designed to interfere with the vascular growth factor signaling pathway have vascular side effects ranging from hypertension to arterial events and cardiomyocyte toxicity. Interestingly, the risk of cardiotoxicity with drugs such as trastuzumab is predicted by preexisting cardiovascular risk factors and disease, posing the question of a vascular component to the pathophysiology. The effect on the coronary circulation has been the leading explanation for the cardiotoxicity of 5-fluorouracil and may be the underlying the mechanism of presentation of apical ballooning syndrome with various chemotherapeutic agents. Classical chemotherapeutic agents such as cisplatin, often used in combination with bleomycin and vinca alkaloids, can lead to vascular events including acute coronary thrombosis and may be associated with an increased long-term cardiovascular risk. This review is intended to provide an update on the evolving spectrum of vascular toxicities with cancer therapeutics, particularly as they pertain to clinical practice, and to the conceptualization of cardiovascular diseases, as well. Vascular toxicity with cancer therapy: the old and the new, an evolving avenue.
A Young Man With Progressive Language Difficulty and Early-Onset Dementia
Botha, Hugo , Jones, Lyell K. , Parisi, Joseph E. , Klaas, James P. , Boeve, Bradley F. , Jones, Lyell K , Botha, Hugo

JAMA Neurology | March 28, 2016 | Volume: 73 | Issue: 5 | Pages: 595

10.1001/jamaneurol.2016.0246 | PMID 27019131 Get It

An MRI‐Based Atlas for Correlation of Imaging and Pathologic Findings in Alzheimer's Disease
Raman, Mekala R., Schwarz, Christopher G. , Murray, Melissa E. , Lowe, Val J. , Jack, Clifford R. , Kantarci, Kejal , Dickson, Dennis W. , Jack, Clifford R , Schwarz, Christopher G , Kantarci, Kejal , Murray, Melissa E

Journal of Neuroimaging | March 28, 2016 | Volume: 26 | Issue: 3 | Pages: 264-268

10.1111/jon.12341 | PMID 27017996 Get It

ABSTRACTBACKGROUND AND PURPOSEPathologic diagnosis is the gold standard in evaluating imaging measures developed as biomarkers for pathologically defined disorders. A brain MRI atlas representing autopsy‐sampled tissue can be used to directly compare imaging and pathology findings. Our objective was to develop a brain MRI atlas representing the cortical regions that are routinely sampled at autopsy for the diagnosis of Alzheimer's disease (AD).METHODSSubjects (n = 22; ages at death = 70‐95) with a range of pathologies and antemortem 3T MRI were included. Histology slides from 8 cortical regions sampled from the left hemisphere at autopsy guided the localization of the atlas regions of interest (ROIs) on each subject's antemortem 3D T1‐weighted MRI. These ROIs were then registered to a common template and combined to form one ROI representing the volume of tissue that was sampled by the pathologists. A subset of the subjects (n = 4; ages at death = 79‐95) had amyloid PET imaging. Density of β‐amyloid immunostain was quantified from the autopsy‐sampled regions in the 4 subjects using a custom‐designed ImageScope algorithm. Median uptake values were calculated in each ROI on the amyloid‐PET images.RESULTSWe found an association between β‐amyloid plaque density in 8 ROIs of the 4 subjects (total ROI n = 32) and median PiB SUVR (r2 = .64; P < .0001).CONCLUSIONSIn an atlas developed for imaging and pathologic correlation studies, we demonstrated that antemortem amyloid burden measured in the atlas ROIs on amyloid PET is strongly correlated with β‐amyloid density measured on histology. This atlas can be used in imaging and pathologic correlation studies.
Targeting childhood, adolescent and young adult non‐Hodgkin lymphoma: therapeutic horizons
Galardy, Paul J. , Hermiston, Michelle L. , Bedekovics, Tibor

British Journal of Haematology | March 28, 2016 | Volume: 173 | Issue: 4 | Pages: 625-636

10.1111/bjh.14016 | PMID 27019108 Get It

SummaryNon‐Hodgkin lymphoma (NHL) is the third most common malignancy in children, adolescents and young adults (CAYA). NHL is a diverse set of diseases that arise at key regulatory checkpoints during B or T cell development in the bone marrow, germinal centre or thymus. While advances in the use of conventional cytotoxic agents have led to dramatic improvements in survival, these cures are associated with significant acute and long‐term toxicities. Moreover, the prognosis for CAYA patients with relapsed or refractory NHL remains dismal, with the vast majority dying of their disease. Thanks to a large number of candidate‐based biological studies, together with large‐scale sequencing efforts, there has been an explosion of knowledge regarding the molecular pathophysiology of B‐ and T‐NHL. This has ushered development of a flurry of novel therapeutic approaches that may simultaneously provide new hope for relapsed patients and an opportunity to reduce the therapeutic burden in newly diagnosed CAYA. Here we review a selection of the most promising new therapeutic approaches to these diseases. While the vast majority of these agents are untested in children, on‐going work from many cooperative groups will soon explore their use in paediatric disease, in hope of further improving outcomes while maximizing quality of life.
Insights into the pathogenic mechanisms of Chromosome 9 open reading frame 72 (C9orf72) repeat expansions
Todd, Tiffany W. , Petrucelli, Leonard

Journal of Neurochemistry | March 26, 2016 | Volume: 138 | Issue: S1 | Pages: 145-162

10.1111/jnc.13623 | PMID 27016280 Get It

AbstractThe identification of a hexanucleotide repeat expansion in a non‐coding region of C9orf72 as a major cause of both frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) drastically changed the field of research on both of these conditions. Yet, despite the vast amount of work aimed at elucidating the molecular mechanisms underlying the role of this repeat in disease, the exact pathomechanisms are still unclear. A reduction in the expression of the C9orf72 gene is observed in patients, but a gain‐of‐function model is now preferred. The hexanucleotide repeat expansion forms RNA foci in the central nervous system (CNS) of repeat‐positive FTD and ALS patients, and these foci are believed to sequester RNA‐binding proteins (RBPs) and impair their function in RNA processing. At the same time, the repeat undergoes repeat‐associated non‐ATG translation to produce dipeptide repeat proteins that also form inclusions in the patient CNS. Studies from cells and flies suggest that these proteins may also be an important factor in the disease. Finally, the hexanucleotide repeat also induces the mislocalization and aggregation of TAR DNA‐binding protein 43 (TDP‐43) through an as yet unknown mechanism. This review covers the different potential pathogenic factors that have been put forth for C9orf72‐repeat‐associated FTD and ALS (C9‐FTD/ALS), while highlighting some remaining questions. image A repeat expansion in C9orf72 is a common cause of both frontal temporal dementia and amyotrophic lateral sclerosis. Although there is a decrease in C9orf72 expression in patients, this repeat is believed to induce disease primarily through an unknown gain‐of‐function mechanism involving the RNA, repeat‐associated non‐AUG translation, or both. This review summarizes and discusses current knowledge on C9orf72 repeat‐associated pathophysiology.This article is part of the Frontotemporal Dementia special issue.
White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network
Lee, Seonjoo , Viqar, Fawad, Zimmerman, Molly E. , Narkhede, Atul, Benzinger, Tammie L.S. , Marcus, Daniel S. , Fagan, Anne M. , Goate, Alison , Fox, Nick C. , Cairns, Nigel J., Buckles, Virginia, Martins, Ralph N. , Saykin, Andrew J. , Masters, Colin L. , Ringman, John M. , Ryan, Natalie S. , Förster, Stefan , Laske, Christoph , Schofield, Peter R. , Salloway, Stephen , Correia, Stephen , Jack, Clifford R. , Weiner, Michael W. , Bateman, Randall J. , Morris, John C. , Mayeux, Richard , Network, for the Dominantly Inherited Alzheimer, Tosto, Giuseppe , Holtzman, David M. , Ghetti, Bernardino , McDade, Eric , Sperling, Reisa Anne , Brickman, Adam M. , Network, for the Dominantly Inherited Alzheimer, Jack, Clifford R , Saykin, Andrew J , Schofield, Peter R , Bateman, Randall J , Masters, Colin L , Benzinger, Tammie L S , Fox, Nick C , Morris, John C , Goate, Alison M

Annals of Neurology | March 26, 2016 | Volume: 79 | Issue: 6 | Pages: 929-939

10.1002/ana.24647 | PMID 27016429 Get It

ObjectiveWhite matter hyperintensities (WMHs) are areas of increased signal on T2‐weighted magnetic resonance imaging (MRI) scans that most commonly reflect small vessel cerebrovascular disease. Increased WMH volume is associated with risk and progression of Alzheimer's disease (AD). These observations are typically interpreted as evidence that vascular abnormalities play an additive, independent role contributing to symptom presentation, but not core features of AD. We examined the severity and distribution of WMH in presymptomatic PSEN1, PSEN2, and APP mutation carriers to determine the extent to which WMH manifest in individuals genetically determined to develop AD.MethodsThe study comprised participants (n = 299; age = 39.03 ± 10.13) from the Dominantly Inherited Alzheimer Network, including 184 (61.5%) with a mutation that results in AD and 115 (38.5%) first‐degree relatives who were noncarrier controls. We calculated the estimated years from expected symptom onset (EYO) by subtracting the affected parent's symptom onset age from the participant's age. Baseline MRI data were analyzed for total and regional WMH. Mixed‐effects piece‐wise linear regression was used to examine WMH differences between carriers and noncarriers with respect to EYO.ResultsMutation carriers had greater total WMH volumes, which appeared to increase approximately 6 years before expected symptom onset. Effects were most prominent for the parietal and occipital lobe, which showed divergent effects as early as 22 years before estimated onset.InterpretationAutosomal‐dominant AD is associated with increased WMH well before expected symptom onset. The findings suggest the possibility that WMHs are a core feature of AD, a potential therapeutic target, and a factor that should be integrated into pathogenic models of the disease. Ann Neurol 2016;79:929–939
Quantitative 3D magnetic resonance elastography: Comparison with dynamic mechanical analysis
Arunachalam, Shivaram P. , Rossman, Phillip J. , Arani, Arvin , Lake, David S. , Glaser, Kevin J. , Trzasko, Joshua D. , McGee, Kiaran P. , Araoz, Philip A. , Manduca, Armando , Ehman, Richard L. , Arunachalam, S P , Arani, Arvin

Magnetic Resonance in Medicine | March 26, 2016 | Volume: 77 | Issue: 3 | Pages: 1184-1192

10.1002/mrm.26207 | PMID 27016276 Get It

Purpose Magnetic resonance elastography (MRE) is a rapidly growing noninvasive imaging technique for measuring tissue mechanical properties in vivo. Previous studies have compared two‐dimensional MRE measurements with material properties from dynamic mechanical analysis (DMA) devices that were limited in frequency range. Advanced DMA technology now allows broad frequency range testing, and three‐dimensional (3D) MRE is increasingly common. The purpose of this study was to compare 3D MRE stiffness measurements with those of DMA over a wide range of frequencies and shear stiffnesses. Methods 3D MRE and DMA were performed on eight different polyvinyl chloride samples over 20–205 Hz with stiffness between 3 and 23 kPa. Driving frequencies were chosen to create 1.1, 2.2, 3.3, 4.4, 5.5, and 6.6 effective wavelengths across the diameter of the cylindrical phantoms. Wave images were analyzed using direct inversion and local frequency estimation algorithm with the curl operator and compared with DMA measurements at each corresponding frequency. Samples with sufficient spatial resolution and with an octahedral shear strain signal‐to‐noise ratio > 3 were compared. Results Consistency between the two techniques was measured with the intraclass correlation coefficient (ICC) and was excellent with an overall ICC of 0.99. Conclusions 3D MRE and DMA showed excellent consistency over a wide range of frequencies and stiffnesses. Magn Reson Med 77:1184–1192, 2017. © 2016 The Authors Magnetic Resonance in Medicine published by Wiley Periodicals, Inc. on behalf of International Society for Magnetic Resonance in Medicine. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.